Bionano Genomics (NASDAQ: BNGO) director awarded 9,149 options

Rhea-AI Filing Summary

Bionano Genomics director Aleksandar Rajkovic received a grant of stock options for 9,149 shares of common stock at an exercise price of $1.19 per share. These options vest in equal monthly installments over 12 months and expire on May 13, 2036.

The award is standard equity compensation, not an open‑market stock purchase or sale. The options will be fully vested by the company’s next annual stockholder meeting or upon a qualifying Change of Control, assuming continuous service through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rajkovic Aleksandar

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,149	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 9,149 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 9,149 options Exercise price: $1.19 per share Underlying shares: 9,149 shares +2 more

5 metrics

Options granted 9,149 options Stock Option (Right to Buy) grant to director

Exercise price $1.19 per share Conversion or exercise price of options

Underlying shares 9,149 shares Common stock underlying granted options

Expiration date May 13, 2036 Option expiration date

Post-grant derivative holdings 9,149 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), Continuous Service, Change of Control, equity incentive plan

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Continuous Service financial

"subject to the option holder's Continuous Service through each such vesting date"

Change of Control financial

"will vest in full upon a Change of Control as defined in the plan"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

equity incentive plan financial

"as defined in the Company's 2018 equity incentive plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rajkovic Aleksandar

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.19	05/14/2026		A		9,149		(1)	05/13/2036	Common Stock	9,149	$0	9,149	D

Explanation of Responses:

1. The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).

	/s/ Jonathan V. Dixon, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Bionano Genomics (BNGO) director Aleksandar Rajkovic report on this Form 4?

He reported receiving a grant of stock options for 9,149 shares of Bionano Genomics common stock. This is a compensation-related award, not a market trade, and reflects additional potential future ownership if the options are exercised.

What is the exercise price and expiration date of the Bionano (BNGO) options granted?

The granted stock options have an exercise price of $1.19 per share and expire on May 13, 2036. The director can choose to exercise the options before expiration, subject to vesting and other plan terms.

How do the Bionano Genomics (BNGO) stock options granted to the director vest?

The 9,149 stock options vest in equal monthly installments over the 12 months following the grant date. They will in any case be fully vested by the next annual stockholder meeting, assuming continuous service through each vesting date.

Are the Bionano (BNGO) option awards to the director tied to continued service?

Yes. Vesting is subject to the option holder’s continuous service as defined in Bionano Genomics’ 2018 equity incentive plan. If service ends before vesting dates, unvested options may be forfeited under the plan’s terms.

What happens to the Bionano Genomics (BNGO) options if there is a Change of Control?

According to the disclosure, the options will vest in full upon a Change of Control, as defined in Bionano Genomics’ 2018 equity incentive plan. This accelerates vesting, giving the director the right to exercise all granted options.